Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.
about
Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14.Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent diseasePeritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancerComparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.New developments in the treatment of ovarian cancer--future perspectives.Expression and biological role of cytoglobin in human ovarian cancer.CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Expression and biological role of δ-catenin in human ovarian cancer.Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway.
P2860
Q34100848-C8D6CA68-9F9F-4550-931F-70EB8381CB18Q34411194-4D059952-1190-4446-97DF-6C541EB0A5ABQ35121648-042CF298-9680-4EAE-8922-1D6BB66994BEQ35674162-7B2278F8-45F1-42C3-8E58-A662B2865937Q36457582-EF4C97EB-8816-4D77-8A5B-0938C8583CF0Q37332487-BC1D65C4-CD48-426E-8AF6-E1FFC037C9F4Q38392066-90407611-5ECE-4CF6-80AC-0D7F380792B0Q38401447-E5EAF61C-5DD8-4A87-99FF-3DB278AEAA79Q38402842-4C09197B-819F-485A-835C-0FB6D3B9A51CQ38994527-82A2E9AD-F989-4601-834F-64BEC4BDBC35Q39241466-5C5A059F-DC43-48F2-918D-957908E08E3DQ43279631-46B67751-2ED5-4ED4-A6B2-516A1D286B8AQ44386340-148DD0C6-3A9F-4AFB-8AE7-8155CE8F1C62Q51415152-4E2035AE-7679-4859-BFD4-FC201DFC92AE
P2860
Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Translational research in the ...... profiles, and novel therapies.
@ast
Translational research in the ...... profiles, and novel therapies.
@en
type
label
Translational research in the ...... profiles, and novel therapies.
@ast
Translational research in the ...... profiles, and novel therapies.
@en
prefLabel
Translational research in the ...... profiles, and novel therapies.
@ast
Translational research in the ...... profiles, and novel therapies.
@en
P2860
P1433
P1476
Translational research in the ...... profiles, and novel therapies.
@en
P2093
Kathleen M Darcy
Michael J Birrer
P2860
P304
P356
10.1016/J.YGYNO.2010.01.048
P407
P577
2010-03-16T00:00:00Z